Copper-binding compounds as proteasome inhibitors and apoptosis inducers in human cancer

Frontiers in Bioscience

Volumn 12, Issue 1, 2007, Pages 135-144

  Daniel, Kenyon G ^a   Chen, Di ^a   Yan, Bing ^b   Ping Dou, Q ^a,c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHANDONG UNIVERSITY   (China)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Cancer; Cell death; Clioquinol; Copper; Penicillamine; Proteasome inhibitors; Pyrrollidine dithiocarbamate; Review; Tetrathiomolybdate; Trientine

Indexed keywords

EID: 34249781706     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2054     Document Type: Article

References (60)

1. Tapiero, H., D. M. Townsend & K. D. Tew: Trace elements in human physiology and pathology. Copper. Biomed Pharmacother, 57, 386-98 (2003)
2. Linder, M.: Biochemistry of Copper. Plenum Press, New York (1991)
3. Turnlund, J. R., W. R. Keyes, H. L. Anderson & L. L. Acord: Copper absorption and retention in young men at three levels of dietary copper by use of the stable isotope 65Cu. Am J Clin Nutr, 49, 870-8 (1989)
4. Predki, P. F. & B. Sarkar: Effect of replacement of "zinc finger" zinc on estrogen receptor DNA interactions. J Biol Chem, 267, 5842-6 (1992)
5. Halliwell, B. & J. M. Gutteridge: Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J, 219, 1-14 (1984)
6. Rizk, S.L & H. H. Sky-Peck: Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Res, 44, 5390-4 (1984)
7. Kuo, H.W., S.F. Chen, C.C. Wu, D.R. Chen, J.H. Lee: Serum and tissue trace elements in patients with breast cancer in Taiwan. Biol Trace Elem Res. 89, 1-11 (2002)
8. Brem, S.: Angiogenesis and Cancer Control: From Concept to Therapeutic Trial. Cancer Control, 6, 436-458 (1999)
9. Brewer, G. J.: Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp Biol Med (Maywood), 226, 665-73 (2001)
10. Theophanides, T. & J. Anastassopoulou: Copper and carcinogenesis. Crit Rev Oncol Hematol, 42, 57-64 (2002)
11. Folkman, J.: Tumor angiogenesis: therapeutic implications. N Engl J Med, 285, 1182-6 (1971)
12. Folkman, J.: Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg, 175, 409-16 (1972)
13. Folkman, J. & M. Klagsbrun: Angiogenic factors. Science, 235, 442-7 (1987)
14. Brewer, G. J.: Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation. J Cell Mol Med, 7, 11-20 (2003)
15. Gullino, P. M.: Considerations on the mechanism of the angiogenic response. Anticancer Res, 6, 153-8 (1986)
16. Fox, S. B., G. Gasparini & A. L. Harris: Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol, 2, 278-89 (2001)
17. Eatock, M. M., A. Schatzlein & S. B. Kaye: Tumour vasculature as a target for anticancer therapy. Cancer Treat Rev, 26, 191-204 (2000)
18. Harris, E. D.: A requirement for copper in angiogenesis. Nutr Rev, 62, 60-4 (2004)
19. Zowczak, M., M. Iskra, L. Torlinski & S. Cofta: Analysis of serum copper and zinc concentrations in cancer patients. In: Biol Trace Elem Res, 82, 1-8 (2001)
20. Turecky, L., P. Kalina, E. Uhlikova, S. Namerova & J. Krizko: Serum ceruloplasmin and copper levels in patients with primary brain tumors. Klin Wochenschr, 62, 187-9 (1984)
21. Hu, G. F.: Copper stimulates proliferation of human endothelial cells under culture. J Cell Biochem, 69, 326-35 (1998)
22. Pan, Q., C. G. Kleer, K. L. van Golen, J. Irani, K. M. Bottema, C. Bias, M. De Carvalho, E. A. Mesri, D. M. Robins, R. D. Dick, G. J. Brewer & S. D. Merajver: Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res, 62, 4854-9 (2002)
23. Daniel, K. G., R. H. Harbach, W. C. Guida & Q. P. Dou: Copper storage diseases: Menkes, Wilsons, and cancer. Front Biosci, 9, 2652-62 (2004)
24. Sarkar, B.: Treatment of Wilson and menkes diseases. Chem Rev, 99, 2535-44 (1999)
25. Brewer, G. J.: Recognition, diagnosis, and management of Wilson's disease. Proc Soc Exp Biol Med, 223, 39-46 (2000)
26. Yoshii, J., H. Yoshiji, S. Kuriyama, Y. Ikenaka, R. Noguchi, H. Okuda, H. Tsujinoue, T. Nakatani, H. Kishida, D. Nakae, D. E. Gomez, M. S. De Lorenzo, A. M. Tejera & H. Fukui: The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int J Cancer, 94, 768-73 (2001)
27. Brem, S. S., D. Zagzag, A. M. Tsanaclis, S. Gately, M. P. Elkouby & S. E. Brien: Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am J Pathol, 137, 1121-42 (1990)
28. Sone, K., M. Maeda, K. Wakabayashi, N. Takeichi, M. Mori, T. Sugimura & M. Nagao: Inhibition of hereditary hepatitis and liver tumor development in Long-Evans cinnamon rats by the copper-chelating agent trientine dihydrochloride. Hepatology, 23, 764-70 (1996)
29. Cox, C., T. N. Teknos, M. Barrios, G. J. Brewer, R. D. Dick & S. D. Merajver: The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope, 111, 696-701 (2001)
30. Brewer, G. J., R. D. Dick, D. K. Grover, V. LeClaire, M. Tseng, M. Wicha, K. Pienta, B. G. Redman, T. Jahan, V. K. Sondak, M. Strawderman, G. LeCarpentier & S. D. Merajver: Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res, 6, 1-10 (2000)
31. Redman, B. G., P. Esper, Q. Pan, R. L. Dunn, H. K. Hussain, T. Chenevert, G. J. Brewer & S. D. Merajver: Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res, 9, 1666-72 (2003)
32. Daniel, K. G., P. Gupta, R. H. Harbach, W. C. Guida & Q. P. Dou: Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem Pharmacol, 67, 1139-51 (2004)
33. Adams, J., V. J. Palombella, E. A. Sausville, J. Johnson, A. Destree, D. D. Lazarus, J. Maas, C. S. Pien, S. Prakash & P. J. Elliott: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res, 59, 2615-22 (1999)
34. An, B., R. H. Goldfarb, R. Siman & Q. P. Dou: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 5 1062-75 (1998)
35. Lopes, U. G., P. Erhardt, R. Yao & G. M. Cooper: p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem, 272, 12893-6 (1997)
36. Imajoh-Ohmi, S., T. Kawaguchi, S. Sugiyama, K. Tanaka, S. Omura & H. Kikuchi: Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun, 217, 1070-7 (1995)
37. Shinohara, K., M. Tomioka, H. Nakano, S. Tone, H. Ito & S. Kawashima: Apoptosis induction resulting from proteasome inhibition. Biochem J, 317 (Pt 2), 385-8 (1996)
38. Drexler, H. C.: Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A, 94, 855-60 (1997)
39. Sun, J., S. Nam, C. S. Lee, B. Li, D. Coppola, A. D. Hamilton, Q. P. Dou & S. M. Sebti: CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAFl and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res, 61, 1280-4 (2001)
40. Adams, J.: Development of the proteasome inhibitor PS-341. Oncologist, 1, 9-16 (2002)
41. Dou, Q. P. & R. H. Goldfarb: Bortezomib (millennium pharmaceuticals) IDrugs, 5, 828-34 (2002)
42. An, W. G., S. G. Hwang, J. B. Trepel & M. V. Blagosklonny: Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia, 14, 1276-83 (2000)
43. Hideshima, T., P. Richardson, D. Chauhan, V. J. Palombella, P. J. Elliott, J. Adams & K. C. Anderson: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res, 61, 3071-6 (2001)
44. Tan, C. & T. A. Waldmann: Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res, 62, 1083-6 (2002)
45. Cherny, R. A., C. S. Atwood, M. E. Xilinas, D. N. Gray, W. D. Jones, C. A. McLean, K. J. Barnham, I. Volitakis, F. W. Fraser, Y. Kim, X. Huang, L. E. Goldstein, R. D. Moir, J. T. Lim, K. Beyreuther, H. Zheng, R. E. Tanzi, C. L. Masters & A. I. Bush: Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron, 30, 665-76 (2001)
46. Yassin, M. S., J. Ekblom, M. Xilinas, C. G. Gottfries & L. Oreland: Changes in uptake of vitamin B (12) and trace metals in brains of mice treated with clioquinol. J Neurol Sci, 173, 40-4 (2000)
47. Richards, D. A.: Prophylactic value of clioquinol against travellers' diarrhoea. Lancet, 1, 44-5 (1971)
48. Cole, G. M.: Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases? Neuron, 37, 889-90 (2003)
49. Ritchie, C. W., A. I. Bush, A. Mackinnon, S. Macfarlane, M. Mastwyk, L. MacGregor, L. Kiers, R. Cherny, Q. X. Li, A. Tammer, D. Carrington, C. Mavros, I. Volitakis, M. Xilinas, D. Ames, S. Davis, K. Beyreuther, R. E. Tanzi & C. L. Masters: Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol, 60, 1685-91 (2003)
50. Regland, B., W. Lehmann, I. Abedini, K. Blennow, M. Jonsson, I. Karlsson, M. Sjogren, A. Wallin, M. Xilinas & C. G. Gottfries: Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord, 12, 408-14 (2001)
51. Di Vaira, M., C. Bazzicalupi, P. Orioli, L. Messori, B. Bruni & P. Zatta: Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc (II) and copper (II) complexes. Inorg Chem, 43, 3795-7 (2004)
52. Pan, Q., L. W. Bao & S. D. Merajver: Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res, 1, 701-6 (2003)
53. Daniel, K. G., D. Chen, S. Orlu, C. Cui, F. R. Miller & Q. P. Dou: Clioquinol and Pyrrolidine Dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res, 7, R897-908 (2005)
54. Ding, W. Q., B. Liu, J. L. Vaught, H. Yamauchi & S. E. Lind: Anticancer activity of the antibiotic clioquinol. Cancer Res, 65, 3389-95 (2005)
55. Schreck, R., B. Meier, D. N. Mannel, W. Droge & P. A. Baeuerle: Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med, 175, 1181-94 (1992)
56. Malaguarnera, L., M. R. Pilastro, R. DiMarco, C. Scifo, M. Renis, M. C. Mazzarino & A. Messina: Cell death in human acute myelogenous leukemic cells induced by pyrrolidinedithiocarbamate Apoptosis, 8, 539-45 (2003)
57. Furuta, S., F. Ortiz, X. Zhu Sun, H. H. Wu, A. Mason & J. Momand: Copper uptake is required for pyrrolidine dithiocarbamate-mediated oxidation and protein level increase of p53 in cells. Biochem J, 365, 639-48 (2002)
58. Parodi, F. E., D. Mao, T. L. Ennis, M. A. Bartoli & R. W. Thompson: Suppression of experimental abdominal aortic aneurysms in mice by treatment with pyrrolidine dithiocarbamate, an antioxidant inhibitor of nuclear factor-kappaB. J Vasc Surg, 41, 479-89 (2005)
59. Cen, D., D. Brayton, B. Shahandeh, F. L. Meyskens, Jr. & P. J. Farmer: Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem, 41, 6914-20 (2004)
60. Chen, D., F. Peng, Q. C. Cui, K. G. Daniel, S. Orlu, J. Liu & Q. P. Dou: Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis. Front Biosci, 10, 2932-9 (2005)